GleamWall
中文EN

VTVT vTv Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1641489 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY216,600.0%
TTM net income YoY67.3%
TTM EPS YoY—
Revenue 3-yr CAGR1,499.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-29.8%
Net margin-20.8%
FCF margin—
EBITDA margin-29.8%

Returns

ROE-11.0%
ROA-8.6%
ROIC (approx.)—
Asset turnover0.41x

Leverage & solvency

Liabilities / assets11.3%
Debt / equity0.00x
Current ratio11.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.83x
Accruals ratio15.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$36.84M$0$0$0$0$17,000
R&D expense$7.53M$8.77M$8.98M$3.91M$7.02M$4.10M$2.83M$2.23M
SG&A expense$4.89M$5.16M$4.60M$3.98M$3.68M$3.62M$3.67M$2.67M
Operating income-$12.43M-$13.93M$23.26M-$7.88M-$10.70M-$7.72M-$6.50M-$4.89M
Pretax income-$11.62M-$13.05M$24.13M-$7.14M-$10.35M-$7.38M-$6.22M-$4.44M
Income tax$0$0$0$0$0$0$0$0
Net income-$11.62M-$13.05M$24.13M-$7.14M-$8.70M-$6.05M-$5.09M-$3.63M
EBITDA-$12.43M-$13.93M$23.26M-$7.88M-$10.70M-$7.72M-$6.49M-$4.87M
EPS (diluted)————————
Balance sheet
Cash & equivalents$77.16M$86.64M$98.09M$88.93M$98.50M$25.92M$31.06M$36.75M
Receivables———————$62,000
Current assets$78.60M$87.59M$98.81M$89.89M$99.46M$26.37M$31.92M$38.11M
PP&E, net————$14,000$16,000$19,000$28,000
Total assets$78.61M$87.59M$98.81M$89.90M$99.49M$26.45M$32.03M$38.27M
Current liabilities$7.02M$7.02M$6.88M$6.64M$10.16M$5.29M$4.32M$5.20M
Total liabilities$8.92M$8.96M$8.85M$25.46M$28.95M$24.04M$23.13M$23.96M
Shareholders' equity$69.69M$78.63M$89.96M$64.44M$70.54M$2.76M$7.92M$12.20M
Cash flow statement
Operating cash flow-$10.19M-$11.44M$9.15M-$9.25M-$5.22M-$5.09M-$5.69M-$4.83M
Financing cash flow$709,000——-$321,000$77.80M-$42,000$0$0
Depreciation & amortization$1,000$1,000$1,000$2,000$2,000$3,000$9,000$22,000
Stock-based compensation$1.97M$1.73M$1.39M$1.02M$1.01M$930,000$813,000$825,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.